ClinicalTrials.gg
CompletedNCT02196129Updated Nov 7, 2018

Immediate Pain Relieving Effects of Sinbaro-3 for Low Back Pain

A Phase 3 interventional study of Sinbaro-3 and Hwangryun in Low Back Pain With Radiculopathy, Low Back Pain Without Radiculopathy and Herniated Intervertebral Disc, sponsored by Jaseng Hospital of Korean Medicine. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2018-11-07.

Sponsored by Jaseng Hospital of Korean Medicine · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Intervertebral Disc Displacement with a site in Korea, Republic of — 4 open to participants now, 6 under way, none of them phase 3. Intervertebral Disc Displacement · Korea, Republic of.

Enrollment
11th of 17
60 · median 69
Started
2014
the only one that year
Phase 3
2 of 27
none open now
Registered
4th of 27
by date
Lead sponsor
3 of 27
Jaseng Hospital of Korean Medicine

Among the 27 studies in Intervertebral Disc Displacement with a site in Korea, Republic of, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2014, is one of 2 in phase 3, and was the 4th registered.

Intervertebral Disc Displacement

474 studies on the registry are indexed under Intervertebral Disc Displacement; 98 are open to participants now.

Browse Intervertebral Disc Displacement studies →

Open to participants now

4 of the 27 studies in Intervertebral Disc Displacement with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 48 Intervertebral Disc Displacement studies recruiting now, 20 (42%) set no upper age limit and 24 (50%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Intervertebral Disc Displacement with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the immediate pain relieving effects of sinbaro-3 pharmaco-acupuncture in patients with low back pain admitted for inpatient care

Read the detailed description

60 patients with LBP with moderate to severe pain(NRS>6) were randomly allocated to 2 groups. The experimental group was treated with sinbaro-3 pharmacoacupuncture and the control group was treated with Hwangryun pharmacoacupuncture. All administrations were limited to 1 session, and comparisons of measurements were made before and after treatment. Primary outcomes were measured using the VAS scale. Post-treatment follow-up will be performed to measure primary outcomes at 30 minutes, 2hours, 4hours, and 6 hours after treatment. Before and after each measurement, the patients are asked to stand up and rotate their torso. At termination of the study, satisfaction levels of the patient's current status will also be collected.

03

Conditions studied

  • Low Back Pain With Radiculopathy
  • Low Back Pain Without Radiculopathy
  • Herniated Intervertebral Disc

Keywords

  • low back pain
  • pharmacoacupuncture
  • sinbaro-3
04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted to a Korean Medicine hospital for low back pain with or without radiculopathy
  • Age between 18 and 69
  • NRS score of >6 on the day of the intervention
  • Voluntary participation with written consent given to study consent form

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of serious disease(s) which are possible causes of back pain such as , vertebral fracture, spinal infection, inflammatory spondylitis, cauda equina compression, etc.
  • Prior diagnosis of other chronic disease(s) which could affect effectiveness or interpretation of treatment results such as cardiovascular disease, diabetic neuropathy, fibromyalgia, rheumatoid arthritis, Alzheimer's disease, epilepsy, etc.
  • Progressive neurologic deficit(s) or concurrent severe neurological symptoms
  • Unsuitable for or at risk of complications from acupuncture treatment such as patients with clotting disorders, severe diabetes with risk of infection, serious cardiovascular disease, or undergoing anticoagulant treatment, etc.
  • Under prescription of , immuno-suppressant drugs, psychiatric medicine, or other medication considered unsuitable for subjects by the researcher
  • Experience of gastroenteric complications after taking NSAIDs or currently undergoing treatment for digestive disorders
  • During pregnancy or suspected pregnancy
  • Subjects considered unsuitable for clinical trial by the researcher
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Sinbaro-3

    1cc Harpagophytum Procumbens(freeze drying) pharmacoacupuncture adminstered to 6 acupoints at the site of pain Administered once and once only before any interventions

    Drug: Sinbaro-3

  • Placebo comparator
    Hwangryun(distillation)

    1cc Hwangryun(distillation) pharmaco-acupuncture administered to 6 acupoints at the site of pain Administered once and once only before any other intervention

    Drug: Hwangryun

Interventions

  • DrugHarpagophytum procumbensStudies of Harpagophytum procumbensHarpagophytum procumbens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain

    Also known as: Harpagophytum Procumbens

  • DrugHwangryun

    1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale

    The patient is asked to stand up and roatate the torso to the left and right, then asked to mark on the visual analogue scale the intensity of the pain they are experiencing

    Time frame: At baseline

  2. Visual Analogue Scale

    The patient is asked to stand up and roatate the torso to the left and right, then asked to mark on the visual analogue scale the intensity of the pain they are experiencing

    Time frame: 30 minutes following treatment

  3. Visual Analogue Scale

    The patient is asked to stand up and roatate the torso to the left and right, then asked to mark on the visual analogue scale the intensity of the pain they are experiencing

    Time frame: 2 hours following treatment

  4. Visual Analogue Scale

    The patient is asked to stand up and roatate the torso to the left and right, then asked to mark on the visual analogue scale the intensity of the pain they are experiencing

    Time frame: 4 hours following treatment

  5. Visual Analogue Scale

    The patient is asked to stand up and roatate the torso to the left and right, then asked to mark on the visual analogue scale the intensity of the pain they are experiencing

    Time frame: 6 hours following treatment

Secondary outcomes

  1. Satisfaction levels

    7-point Likert scale

    Time frame: 6hrs following treatment

Other outcomes

  1. Expected treatment effects

    The patients are asked to reply how effective they think the treatment is going to be on a 6-point Likert-scale

    Time frame: At baseline

07

Study locations

1 site
  • Jaseng Hospital of Korean Medicine
    Seoul, Gangnam-Gu 135-896, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Oct 2014, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2014
First posted
Jul 21, 2014
StartActual
Jul 2014
Primary completionActual
Oct 2014
CompletionActual
Nov 2014
Last update
Nov 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02196129
Lead sponsor
Jaseng Hospital of Korean Medicine
Responsible party
In-Hyuk Ha (Dr, Jaseng Hospital of Korean Medicine) — Principal investigator
First posted
Jul 21, 2014
Start date
Jul 2014
Primary completion
Oct 2014
Completion
Nov 2014
Last update
Nov 7, 2018

Study contacts

Joonshik Shin
principal investigator · Jaseng Hospital of Korean Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Harpagophytum procumbens

Start the discussion